Objectives: The objective of this study was to assess and compare the sentinel lymph node (SLN) detection rate with indocyanine green (ICG) and near-infrared fluorescence imaging versus blue dye using the robotic platform in patients with uterine cancer. Methods: We identified all patients with uterine cancer undergoing SLN mapping using ICG or blue dye on the robotic platform from January 2011 to December 2013. Our institutional SLN algorithm and pathologic processing protocol were adhered to uniformly. We compared detection rates of SLNs stratified by dye used. Appropriate statistical tests were used. Results: A total of 472 patients were identified. ICG was used in 312 patients (66%) and blue dye in 160 patients (34%). Successful mapping was achieved in 425 (90%) of 472 patients. Mapping was bilateral in 352 patients (75%) and unilateral in 73 patients (15%); 47 patients (10%) did not map. Successful mapping was achieved in 295 (95%) of 312 patients using ICG compared with 130 (81%) of 160 patients using blue dye (P G 0.001). Mapping was bilateral in 266 (85%) of 312 patients in the ICG group compared with 86 (54%) of 160 in the blue dye group (P G 0.001). Additional lymph node dissection beyond removal of the SLNs was performed in 122 patients (39%) mapped with ICG compared with 98 patients (61%) mapped with blue dye (P G 0.001). Conclusions: The SLN detection rate was superior when mapping with ICG rather than blue dye. Bilateral mapping was significantly improved, resulting in a lower rate of additional lymphadenectomy.
T he use of sentinel lymph node (SLN) mapping in combination with pathologic ultrastaging has gained increasing acceptance in the nodal assessment of patients with endometrial carcinoma. The techniques involved in the SLN approach with regard to injection site and preferred dye are still debatable and evolving. A successful SLN mapping is considered one in which an SLN(s) is identified in both hemipelvises (ie, ''bilateral mapping''). SLN detection rates of approximately 50% have been reported. 1Y3 Failed mapping will often lead to a more extensive lymphadenectomy. Therefore, maximizing detection rates is important. A bilateral SLN mapping rate of 69% was achieved when using both radioisotope and colorimetric tracers in the Senti-Endo trial. 1 More recently, How et al 4 reported a bilateral mapping rate of 65% with indocyanine green (ICG) and technetium. The use of radioisotope (eg, technetium) can be painful for the patient, is associated with logistical issues, and adds cost. The added value of technetium is debatable, and we have abandoned its use in favor of intraoperative dye-basedYonly SLN mapping techniques. We initially used blue dyes (isosulfan blue or methylene blue) and subsequently moved on to fluorescent dyes. The primary objective of this study was to assess and compare the SLN detection rate for uterine cancer using ICG and near-infrared (NIR) fluorescence imaging versus blue dye with the robotic platform at a single institution.
METHODS
Institutional review board approval was obtained for this retrospective study. We identified all patients with complex atypical hyperplasia and uterine cancer undergoing SLN mapping with either ICG or blue dye on the robotic platform from January 2011 to December 2013. All dyes were injected similarly into the cervix only. The concentration of ICG used was 1.25 mg/mL. A 25-mg vial with ICG powder was diluted into 20 cm 3 of aqueous sterile water. A total of 4 cm 3 of this ICG solution was then injected into the cervix, 1 cm 3 deep into the stroma and 1 cm 3 submucosally at the 3 and 9 o'clock positions once the patient was prepped and draped. Isosulfan blue was injected using the same method. The cervix was injected before the insertion of any uterine manipulator. Our previously published institutional SLN algorithm 5 and pathologic processing protocol 6 were adhered to uniformly. The institutional SLN algorithm at the Memorial Sloan Kettering Cancer Center is as follows: upon entry into the abdominal cavity, peritoneal and serosal evaluations as well as washings are performed. This is followed by a retroperitoneal evaluation and excision of all mapped SLNs. Any suspicious nodes must be removed regardless of mapping. If there is no mapping of a hemipelvis, an ipsilateral lymph node dissection (LND) is performed. A paraaortic LND is performed at the attending's discretion. As part of the SLN algorithm, excised lymph nodes are submitted for ultrastaging. An initial examination is performed using hematoxylin and eosin staining; if the hematoxylin and eosin assessment is negative and myometrial invasive carcinoma is found, then serial sectioning and ultrastaging are performed.
Demographic, surgical, and pathologic data were abstracted. We compared the overall detection rates of SLN, bilateral detection rates of SLN, SLN time, and operative (OR) time stratified by dye used. We also looked at additional LND performed and anatomic distribution of detected SLNs. Median age, estimated blood loss (EBL), and SLN counts were noted. We also investigated the accuracy of lymphatic tissue identified in reported SLNs and whether the number of SLNs resected affected SLN time. Characteristics influencing absence of mapping for patients injected with ICG were also investigated. The Fisher exact test or Wilcoxon rank sum test was used to test the 2-way associations depending on whether a continuous variable was included or not. Kruskal-Wallis test was used to investigate the relationship between EBL and body mass index (BMI) category. The LND, SLN mapping, and histology 3-way association was tested using the Cochran-Mantel-Haenszel test. The relationship between SLN time and SLN number was evaluated using Pearson correlation coefficient. The SAS 9.2 was used to perform all statistical tests.
RESULTS
A total of 472 patients were identified. The ICG was used in 312 patients (66%) and blue dye in 160 patients (34%). The ICG and blue dye groups were similar in clinical demographics and intraoperative characteristics (Table 1) . Successful mapping was achieved in 425 (90%) of 472 patients. Mapping was bilateral in 352 patients (75%) and unilateral in 73 patients (15%); 47 patients (10%) did not map. Successful mapping was achieved in 295 (95%) of 312 patients using ICG compared with 130 (81%) of 160 patients using blue dye (P G 0.001). Bilateral mapping occurred in 266 (85%) of 312 patients in the ICG group compared with 86 (54%) of 160 patients in the blue dye group (P G 0.001). Additional LND beyond the removal of the SLNs was performed in 122 patients (39%) mapped with ICG compared with 98 patients (61%) mapped with blue dye (P G 0.001; Table 2 ). Patients with unsuccessful mapping in the ICG subgroup had a significantly higher BMI than those who mapped (median, 36.6 vs 30.3; P = 0.015); they also had a significantly greater EBL (median, 100 vs 50 cm 3 ; P e 0.001). When examining the relationship between BMI and EBL in these patients, they were not independent factors for unsuccessful mapping (P = 0.014).
A total of 191 patients had both SLNs and additional lymph nodes submitted for pathology review; among these, 97% of SLNs (185/191) were identified as lymphatic tissue compared with 94% (179/191) of additional lymph nodes (P = 0.16). For the 413 patients in whom an SLN was detected, the median SLN count was 3 (range, 1Y15). For the 59 patients in whom an SLN was not detected, the median number of lymph nodes other than SLNs was 3 (range, 0Y46). With regard to anatomic distribution of SLNs, 490 (36%) of 1368 SLNs were located in the hypogastric basin, 453 (33%) in the external iliac basin, 313 (23%) in the obturator basin, 83 (6%) in the common iliac basin, 25 (2%) in the aortic basin, and 4 (0.3%) in the presacral basin. A total of 23 (92%) of 25 aortic SLNs were detected using ICG.
The median OR time was 242 minutes (range, 141Y498 minutes) for the entire cohort, 240 minutes (range, 145Y444 minutes) for the ICG group, and 248 minutes (range, 141Y498 minutes) for the blue dye group (P = 0.045). Of the 425 patients who had successful intraoperative mapping, the OR time spent specifically on SLN dissection was available for 279 patients (66%).
Median SLN times were 26 minutes for both the ICG and blue dye groups (P = 1). A scatterplot for SLN time versus SLN number is depicted in Figure 1 . The Pearson correlation coefficient for the SLN time and SLN number was 0.07, which means there was no relationship between the 2 variables.
When stratifying additional LND by SLN mapping and histology for patients with bilateral mapping, 70 (27%) of 260 patients with complex atypical hyperplasia or grade 1/2 disease of endometrioid histology underwent additional LND compared with 66 (72%) of 92 patients with grade 3 disease of endometrioid histology or high-risk histology (3-way test, P G 0.001). A subset analysis showed that for complex atypical hyperplasia or grade 1/2 disease of endometrioid histology group, there was a significant association between additional LND and mapping (P G 0.001), whereas for the endometrioid histology or high-risk histology group, there was not a significant association between additional LND and mapping (P = 0.39; Table 3 ).
DISCUSSION
With the emerging acceptance of an SLN approach to the surgical staging of uterine cancer, it is important to ensure that we use techniques that are reliable, feasible, and acceptable to patients. Previous publications have reported bilateral detection rates of approximately 50% with blue dye, 1Y3 with the remaining 50% requiring additional LND in either 1 or both hemipelvises. We previously reported on our experience of SLN detection with ICG alone compared with ICG and blue dye in 227 cases with endometrial and cervical malignancies. 7 In the current study, we sought to compare the detection rates using blue dye alone or ICG alone. We limited our patient selection to only include patients who had undergone surgical staging of uterine cancer with the robotic platform. Our institution introduced the SLN approach for endometrial and cervical cancer patients in 2003, and has since developed an algorithm decreasing the false-negative rate from 15% to 2%. 5 Our attending surgeons are experienced in this approach, and all had performed more than the estimated 30-case learning curve 8 before the inclusion period. The difference observed between dyes used is not likely attributed to an insufficient experience during the earlier period of this study when blue dye alone was used.
In this study, we observed a significant difference in both overall and bilateral detection rates in favor of ICG. Successful bilateral mapping occurred in 85% of the patients in the ICG group compared with 54% in the blue dye group. When investigating the need for additional lymph node removal, we found that additional LND beyond removal of the SLNs occurred in 39% of ICG cases versus 61% of cases with blue dye. The purpose of the SLN algorithm is to reliably stage endometrial cancer while sparing patients the morbidity associated with complete lymphadenectomy. 9 Incorporating a cervical injection of ICG in combination with NIR fluorescence imaging significantly contributes to this goal. How et al 4 reported an overall detection rate of 92% and bilateral detection rate of 76% when using blue dye, ICG, and technetium-99m. The ICG and 99mTc-sulphur colloid had similar SLN detection rates in both overall (87% vs 88%) and bilateral (71% vs 65%) detection, respectively. The use of radioisotope presents a logistical challenge, added pain and discomfort for the patient, and additional cost. In our study, we found that ICG alone provides a bilateral detection rate similar to that of the overall ICG and 99mTc-sulphur colloid detection rate reported by How et al. 4 Based on our findings, we cannot justify the added cost and patient discomfort associated with the use of radioisotope, and we suggest using ICG alone when this technique is available.
When investigating clinical factors that could have influenced the absence of mapping in patients in whom ICG was used, we found that BMI and EBL were significantly higher in those patients with unsuccessful mapping. On further investigation, there was a significant correlation where patients with increased BMI had a greater EBL. We recommend gentle dissection to minimize rupture of lymphatic channels and bleeding, to avoid ICG contamination, which in turn can compromise the identification of the SLNs.
There was no difference in the median OR times or SLN times between ICG and blue dye in this study. There was no correlation between SLN time and SLN number (Fig. 1) . This may suggest that it is the time spent opening the anatomic spaces and searching for the lymphatic channels to guide the surgeon to the SLNs that takes time. The mere extraction of the individual SLNs, once identified, is not time consuming. This is in line with our previously reported findings that there is a correlation between SLN time and increasing BMI. 10 One of the potential benefits of transitioning from complete lymphadenectomy to an SLN approach is reducing OR time. It is, however, of utmost importance to do a systematic search for lymphatic channels and nodes to ensure that the correct nodes are identified and extracted. This part of the procedure should not be rushed.
One of the concerns raised with regard to implementing an SLN approach in favor of complete lymphadenectomy is the omission of para-aortic lymph node removal and assessment, which may preclude the detection of metastatic disease in this region. In this study, 25 (2%) of 1368 SLNs were located in the aortic basin, of which 23 (92%) were detected using ICG. Although nodal metastasis to the para-aortic nodes is rare when there is no metastasis to the pelvis, 11, 12 these findings further support the use of ICG and NIR fluorescence imaging over blue dye.
When investigating the accuracy of lymphatic tissue identified by pathology review, the submitted SLNs were identified as such more frequently than were the additional lymph nodes. This did not reach statistical significance; however, it A subset analysis showed no significant association between additional LND and mapping for patients with high-risk histology. From this, we can conclude that our surgeons performed additional lymph node sampling in these high-risk patients irrespective of mapping. This is reasonable and reflects the lack of prospective data in this area and is also in line with the current National Comprehensive Cancer Network guidelines. 13 Retrospective data comparing an SLN algorithm to lymphadenectomy using Mayo criteria in intermediate-and high-risk patients found that in intermediate-risk patients, defined as those with disease of endometrioid histology of any grade and greater than 50% myometrial invasion, there was a similar detection rate of stage IIIC disease between the SLN and LND cohorts, however with more stage IIIC1 disease detected in the SLN cohort and more stage IIIC2 disease noted in the LND cohort.
14 For high-risk patients, defined as those with disease of serous and clear cell histologies, there were similar detection rates of stage IIIC1 and IIIC2 disease with both approaches. Overall, stage IIIC disease was diagnosed at similar rates in each cohort, with fewer lymph nodes removed in the SLN group. Once stage IIIC disease is detected, these patients will receive adjuvant therapy based on local guidelines. It is therefore uncertain if the removal of more lymph nodes will affect survival. Although they have been criticized, the results from 2 randomized trials on lymphadenectomy in endometrial cancer indicate that the omission of a complete lymphadenectomy does not affect survival. 15, 16 Further studies are needed with regard to oncologic outcomes when applying an SLN algorithm in patients with high-risk histology to guide strategy in the surgical staging of this patient population.
In conclusion, SLN detection rate is superior when using ICG rather than blue dye. Importantly, bilateral mapping is significantly improved using ICG and NIR fluorescence imaging, resulting in a lower rate of additional lymphadenectomy, and the detection of para-aortic SLNs is significantly increased when using ICG. These data favor the use of ICG cervical injection over blue dye in the surgical staging of uterine cancer.
